The cytosolic space of cells is an important target for drug delivery systems since many therapeutic agents are aimed at intervening or modifying specific molecular events occurring in the cytoplasm of cells. Many of these therapeutic agents, particularly the ones discovered or designed in recent years, are intrinsically membrane-permeant due to their charge or high molecular weight. The long term objective of this proposal is to develop strategies and methods that can deliver molecules in this category into the cytosolic space of cells. The main idea of this proposal is to import cell biology and biochemistry of Listeria into pharmaceutics, i.e., to take a minimal component from a facultative intracellular bacterium, Listeria monocytogenes, and construct a liposome-based cytosolic delivery vehicle. Listeriolysin O (LLO), which is necessary and sufficient in the escape of Listeria into cytosol, will be purified and incorporated into liposomes. The LLO-containing liposomes, which mimic how Listeria deliver themselves into the cytosol where they grow, will be characterized in terms of their ability to delivery macromolecules into the cytosol. Although the proposed strategy should be applicable to the delivery of other types of macromolecules, the current proposal will focus on the delivery of proteinaceous macromolecules. Two types of proteins that show effect when delivered into the cytosol will be tested: (1) an antigenic protein that induces activation of specific cytotoxic T lymphocytes (CTL); and (2) toxins that can inhibit protein synthesis. The amount of cytosolic delivery will be measured by a newly developed biochemical assay which monitors the percent of cytosolically delivered molecules out of the total cell-associated amount. In vitro antigen presentation assays will also be employed to measure relative efficiency of delivery into the cytosolic pathway of antigen presentation. This has direct implications as a vaccine delivery vehicle, and will therefore be extended to a well-established mouse model of lymphocytic choriomeningitis virus (LCMV) infection. Induction of CTL, specific against nucleoprotein (NP) of LCMV, by NP-containing LLO-liposomes and subsequent protection from viral challenge will be monitored in mice. In addition to delivering antigenic proteins, a membrane-impermeant toxin, gelonin, will be encapsulated inside LLO-liposomes and tested in the cell growth inhibition assays. The liposome formations that have a long circulation time will be made with LLO, and their efficiency of cytosolic delivery will also be tested. Concurrently, the mechanism of endosome lysis by LLO via pore formation will be studied using biophysical and molecular biological methods.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29AI042084-03
Application #
6149860
Study Section
Pharmacology A Study Section (PHRA)
Program Officer
Hecht, Toby T
Project Start
1998-02-01
Project End
2003-01-31
Budget Start
2000-02-01
Budget End
2001-01-31
Support Year
3
Fiscal Year
2000
Total Cost
$96,232
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Mandal, Manas; Kawamura, Kim S; Wherry, E John et al. (2004) Cytosolic delivery of viral nucleoprotein by listeriolysin O-liposome induces enhanced specific cytotoxic T lymphocyte response and protective immunity. Mol Pharm 1:2-8
Park, Chung-Gyu; Thiex, Natalie W; Lee, Kyung-Mi et al. (2003) Targeting and blocking B7 costimulatory molecules on antigen-presenting cells using CTLA4Ig-conjugated liposomes: in vitro characterization and in vivo factors affecting biodistribution. Pharm Res 20:1239-48
Mathew, E; Hardee, G E; Bennett, C F et al. (2003) Cytosolic delivery of antisense oligonucleotides by listeriolysin O-containing liposomes. Gene Ther 10:1105-15
Provoda, Chester J; Stier, Ethan M; Lee, Kyung-Dall (2003) Tumor cell killing enabled by listeriolysin O-liposome-mediated delivery of the protein toxin gelonin. J Biol Chem 278:35102-8
Mandal, Manas; Mathew, Elizabeth; Provoda, Chester et al. (2003) Delivery of macromolecules into cytosol using liposomes containing hemolysin. Methods Enzymol 372:319-39
Saito, G; Amidon, G L; Lee, K-D (2003) Enhanced cytosolic delivery of plasmid DNA by a sulfhydryl-activatable listeriolysin O/protamine conjugate utilizing cellular reducing potential. Gene Ther 10:72-83
O'Riordan, Mary; Yi, Caroline H; Gonzales, Ramona et al. (2002) Innate recognition of bacteria by a macrophage cytosolic surveillance pathway. Proc Natl Acad Sci U S A 99:13861-6
Mandal, Manas; Lee, Kyung-Dall (2002) Listeriolysin O-liposome-mediated cytosolic delivery of macromolecule antigen in vivo: enhancement of antigen-specific cytotoxic T lymphocyte frequency, activity, and tumor protection. Biochim Biophys Acta 1563:7-17
Larson, G M; Lee, K D (1998) Macromolecular cytosolic delivery: cell membranes as the primary obstacle. Arch Pharm Res 21:621-8